Investigation of Acquired Resistance to EGFR-Targeted Therapies in Lung Cancer Using cDNA Microarrays

摘要: Clinical tools to accurately describe, evaluate, and predict an individual's response cancer therapy are a field-wide priority; in many advanced cancers, only 10-20% of individuals will have clinical benefit from therapy, yet we treat the entire population. Furthermore, therapies initially effective, but lose effectiveness over time. Here describe methods derive vitro models resistance EGFR tyrosine kinase inhibitors. We additionally approaches characterize possible mechanisms by genomic transcriptomic approaches.